Global PSMA-PET Tracer Market Strategic Research Report

Scope of the Report

The global PSMA-PET Tracer market size is predicted to grow from US$ 1,731 million in 2025 to US$ 2,839 million in 2032; it is expected to grow at a CAGR of 7.4% from 2026 to 2032.

In 2025, the global production of PSMA‑PET tracer reached 3,539,400 units, with an average selling price of US$500 per unit. The global annual production capacity of PSMA‑PET tracer was approximately 5,000,000 units, and the gross margin was about 30.4%. PSMA‑PET tracer is a radiopharmaceutical used for the diagnosis and staging of prostate cancer. PSMA (prostate‑specific membrane antigen) is a membrane protein that is highly expressed on the surface of prostate cancer cells but shows very low expression in normal tissues. PET tracers are agents labeled with positron‑emitting radionuclides that can be visualized by PET scanning. The active ingredients in the tracer, such as PSMA‑617 and PSMA‑11 ligands, specifically bind to PSMA protein, and the carried radionuclides (e.g., ⁶⁸Ga, ¹⁸F) emit positrons, which are detected by PET scanning to precisely locate prostate cancer lesions. The upstream of PSMA‑PET tracer includes radionuclides (such as gallium‑68, fluorine‑18, etc.), PSMA‑targeting ligands (small molecules, peptides, or antibodies), and nanocarriers/chelating agents. The midstream consists of manufacturers of PSMA‑PET tracer, and the downstream is mainly applied in nuclear medicine and molecular imaging, precision diagnosis of tumors, and radiopharmaceuticals and nuclear medicine.

The current market for PSMA‑PET tracer is experiencing rapid growth, mainly fueled by the rising demand for precision diagnosis and treatment of prostate cancer, along with continuous advances in molecular imaging and radiopharmaceutical technologies. This tracer has progressively expanded from early research settings into routine clinical practice, playing an increasingly important role in initial staging, biochemical recurrence detection, and treatment response assessment for prostate cancer. Despite its broad clinical potential, the market still faces challenges such as regional distribution constraints caused by short radionuclide half‑lives, insufficient standardization in production and quality control, and discrepancies in reimbursement policies and clinical guidelines across different countries and regions. At the same time, active research into novel ligand design, radionuclide labeling optimization, and multimodal imaging strategies is continuously enriching product pipelines and expanding application scenarios, steering the overall market toward higher efficiency and greater precision, while the competitive landscape becomes increasingly diverse and specialized.

Key Questions Addressed in this Report

What is the 10-year outlook for the global PSMA-PET Tracer market?

What factors are driving PSMA-PET Tracer market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do PSMA-PET Tracer market opportunities vary by end market size?

How does PSMA-PET Tracer break out by Type, by Application?

This report presents a comprehensive overview of the global PSMA-PET Tracer market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 68Ga
• 18F

Segment by Core Carrier Materials

• First Generation
• Second Generation

Segment by Mechanism of Action

• Active Targeting
• Passive Targeting

Segment by Application

• Nuclear Medicine and Molecular Imaging
• Precision Oncology Diagnostics
• Radiopharmaceuticals and Radiopharmaceuticals

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global PSMA-PET Tracer market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Nuclear Medicine and Molecular Imaging, Precision Oncology Diagnostics, Radiopharmaceuticals and Radiopharmaceuticals evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact